Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.54 |
| ▸ | RAF1 | P04049 | 6/20 | 0.48 |
| ▸ | BRAF | P15056 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454154 | 0.95 | BRAF (0.52) | BTKRAF1BRAFLMNA | |
| SCHEMBL6454592 | 0.93 | MAPT (0.52) | BTKKDRMAPTSTAT3SMN1; SMN2 | |
| SCHEMBL6450183 | 0.90 | ABL1 (0.52) | BTKRAF1BRAFSCN9AMAPK14 | |
| SCHEMBL6461342 | 0.88 | EGFR (0.51) | EPHX2MAPK14MAPTSMN1; SMN2 | |
| SCHEMBL6454347 | 0.84 | MAPT (0.49) | RAF1EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL5031557 | 0.77 | MAPT (0.56) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL6454372 | 0.74 | CSF1R (0.55) | RAF1BRAFKDRCSF1RMAPK14 | |
| SCHEMBL4699433 | 0.73 | MAPK14 (0.58) | RAF1BRAFCSF1RMAPK14 | |
| SCHEMBL6461376 | 0.73 | CSF1R (0.54) | RAF1BRAFKDRCSF1R | |
| SCHEMBL6455326 | 0.73 | PIP4K2A (0.55) | BRAFCSF1RMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | claimed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | LCK, FYN, BMX | BTK 19/4885RAF1 6/4885BRAF 7/4885 |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | LCK, FYN, BMX | BTK 19/4885RAF1 6/4885BRAF 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.